Foundation Medicine Appoints Steven J. Kafka, Ph.D. as Chief Business Officer

  Foundation Medicine Appoints Steven J. Kafka, Ph.D. as Chief Business
  Officer

Business Wire

CAMBRIDGE, Mass. -- January 23, 2013

Foundation Medicine, Inc., a molecular information company that brings
comprehensive cancer genomic analysis to routine clinical care, today
announced the appointment of Steven J. Kafka, Ph.D. to the newly created
position of chief business officer. In this role, he will have broad
responsibility for business development and operational functions.

“Foundation Medicine is poised to expand the community of physicians, cancer
centers and pharmaceutical partners utilizing our services,” said Michael J.
Pellini, M.D., president and chief executive officer. “Steve brings a valuable
combination of strategic planning, financial and operational expertise to help
us drive capacity enhancements in our world-class CLIA-licensed laboratory, as
well as a strong track record of building and leading successful
pharmaceutical partnerships. On behalf of the whole team, it’s our pleasure
welcome Steve to Foundation Medicine.”

Dr. Kafka brings over 15 years of business and strategy experience in the
pharmaceutical and biotechnology industries, with a focus on targeted
therapies in oncology. He joins the company from Aileron Therapeutics where he
served as chief operating officer and chief financial officer. At Aileron, Dr.
Kafka led the company's operations, finance, and human resources functions,
and helped to secure a major collaboration with Roche worth up to $1.1
billion.

Prior to Aileron, Dr. Kafka led finance, investor and public relations and
business operations as vice president of finance for Infinity Pharmaceuticals
(NASDAQ: INFI). While at Infinity, he worked on a number of innovative
collaborations with leading pharmaceutical companies, including the company’s
strategic alliance with Purdue Pharmaceuticals. Earlier in his career, Dr.
Kafka was senior director of finance at Millennium Pharmaceuticals, where he
was a key member of the product team in driving strategic planning and
alliance management efforts for VELCADE®, a novel targeted cancer therapeutic.
Dr. Kafka earned his Ph.D. from Harvard University and his B.A. with
Distinction and Honors from Stanford University.

“Foundation Medicine is leading a transformation in cancer care where each
patient’s cancer can be treated at the level of its molecular blueprint,” said
Dr. Kafka. “By helping to expand the availability of advanced genomic analysis
and rational targeted therapies, we are working to ensure that physicians in
communities across the world can select the right treatment at the right time
for each patient’s individual cancer. I am delighted to join Foundation
Medicine in this mission.”

About Foundation Medicine

Foundation Medicine^® is a molecular information company dedicated to a
transformation in cancer care in which treatment is informed by a deep
understanding of the genomic changes that contribute to each patient’s unique
cancer. The company’s initial clinical assay, FoundationOne^TM, is a fully
informative genomic profile to identify a patient’s individual molecular
alterations and match them with relevant targeted therapies and clinical
trials. Foundation Medicine’s molecular information platform aims to improve
day-to-day care for patients by serving the needs of clinicians, academic
researchers and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit
www.FoundationMedicine.com or follow Foundation Medicine on Twitter
(@FoundationATCG).

VELCADE® is a registered trademark of Millennium Pharmaceuticals, Inc.
Foundation Medicine® is a registered trademark, and FoundationOne^TM is a
trademark of Foundation Medicine, Inc.

Contact:

Pure Communications, Inc.
Dan Budwick, 973-271-6085
 
Press spacebar to pause and continue. Press esc to stop.